Debrisoquin

Summary

Debrisoquin (CHEMBL169901) is an approved small-molecule antihypertensive agent (ATC C02CC04); indicated across 1 condition including hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02CC04
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 175.23 Da · C10H13N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL169901
Name	Debrisoquin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2966
ChEBI	CHEBI:34665
ATC	C02CC04
Molecular formula	C10H13N3
Molecular weight	175.23
InChIKey	JWPGJSVJDAJRLW-UHFFFAOYSA-N

SMILES: C1CN(CC2=CC=CC=C21)C(=N)N

IUPAC name: 3,4-dihydro-1H-isoquinoline-2-carboximidamide

Pharmacological roles (ChEBI): antihypertensive agent, adrenergic agent, sympatholytic agent.

Other ChEBI roles (chemical / environmental): human metabolite.

Also known as: Debrisoquina, Debrisoquine, Debrisoquin, SID11112418, DEBRISOQUIN, debrisoquin, DEBRISOQUIN SULFATE, DEBRISOQUINE, debrisoquine

Parent form; salt/anhydrous children: CHEMBL1255735, CHEMBL1593558, CHEMBL3527581

Patent coverage: 378 distinct patent families (1,047 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,010 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Transmembrane protease serine 2, Alpha-2A adrenergic receptor, Amine oxidase [flavin-containing] A, 5-hydroxytryptamine receptor 1A, Sodium-dependent noradrenaline transporter, Cytochrome P450 2D6.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	5.56	AC50	2765	nM	CHEMBL_ACT_25164799
MAOA	5.37	AC50	4316	nM	CHEMBL_ACT_25160466

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00162383	Not specified	UNKNOWN	Metabolic Capacity of Israeli Populations

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 39 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).